VYNE Therapeutics Inc. (VYNE)
VYNE Stock Price Chart
Explore VYNE Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze VYNE price movements and trends.
VYNE Company Profile
Discover essential business fundamentals and corporate details for VYNE Therapeutics Inc. (VYNE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Jan 2018
Employees
13.00
Website
https://www.vynetherapeutics.comCEO
David T. Domzalski
Description
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
VYNE Financial Timeline
Browse a chronological timeline of VYNE Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.18, while revenue estimate is $200.00k.
Dividend declared on 22 Jul 2026
A dividend of $0.38 per share was announced, adjusted to $0.38. The dividend will be paid on 23 Jul 2026.
Earnings released on 15 May 2026
EPS came in at -$0.08 surpassing the estimated -$0.18 by +55.56%, while revenue for the quarter reached $86.00k , missing expectations by -57.00%.
Earnings released on 12 Mar 2026
EPS came in at -$0.28 falling short of the estimated -$0.20 by -40.00%, while revenue for the quarter reached $130.00k , missing expectations by -25.71%.
Earnings released on 6 Nov 2025
EPS came in at -$0.17 surpassing the estimated -$0.19 by +10.53%, while revenue for the quarter reached $169.00k , beating expectations by +35.20%.
Earnings released on 14 Aug 2025
EPS came in at -$0.13 surpassing the estimated -$0.23 by +43.48%, while revenue for the quarter reached $69.00k , missing expectations by -65.50%.
Earnings released on 8 May 2025
EPS came in at -$0.20 surpassing the estimated -$0.29 by +31.03%, while revenue for the quarter reached $202.00k , beating expectations by +304.00%.
Earnings released on 6 Mar 2025
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%, while revenue for the quarter reached $84.00k , missing expectations by -16.00%.
Earnings released on 7 Nov 2024
EPS came in at -$0.29 falling short of the estimated -$0.24 by -20.83%, while revenue for the quarter reached $121.00k , missing expectations by -13.57%.
Earnings released on 14 Aug 2024
EPS came in at -$0.22 falling short of the estimated -$0.19 by -15.79%, while revenue for the quarter reached $198.00k , beating expectations by +80.00%.
Earnings released on 9 May 2024
EPS came in at -$0.15 surpassing the estimated -$0.24 by +37.50%, while revenue for the quarter reached $98.00k , missing expectations by -10.91%.
Earnings released on 29 Feb 2024
EPS came in at -$0.20 surpassing the estimated -$0.50 by +60.00%, while revenue for the quarter reached $76.00k , missing expectations by -49.33%.
Earnings released on 13 Nov 2023
EPS came in at -$1.85 falling short of the estimated -$0.76 by -143.42%, while revenue for the quarter reached $114.00k , missing expectations by -24.00%.
Earnings released on 14 Aug 2023
EPS came in at -$3.08 falling short of the estimated -$1.99 by -54.77%, while revenue for the quarter reached $135.00k , beating expectations by +35.00%.
Earnings released on 11 May 2023
EPS came in at -$1.74 surpassing the estimated -$2.50 by +30.40%, while revenue for the quarter reached $99.00k .
Earnings released on 9 Mar 2023
EPS came in at -$2.60 surpassing the estimated -$3.24 by +19.75%, while revenue for the quarter reached $6.00k , missing expectations by -90.00%.
Stock split effective on 13 Feb 2023
Shares were split 1 : 18 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2022
EPS came in at -$2.88 matching the estimated -$2.88, while revenue for the quarter reached $167.00k , beating expectations by +234.00%.
Earnings released on 12 Aug 2022
EPS came in at -$2.34 surpassing the estimated -$2.70 by +13.33%, while revenue for the quarter reached $126.00k , beating expectations by +26.00%.
Earnings released on 12 May 2022
EPS came in at -$2.52 surpassing the estimated -$2.70 by +6.67%, while revenue for the quarter reached $178.00k , missing expectations by -51.45%.
Earnings released on 17 Mar 2022
EPS came in at -$3.60 surpassing the estimated -$4.68 by +23.08%, while revenue for the quarter reached $2.29m , missing expectations by -42.99%.
Earnings released on 10 Nov 2021
EPS came in at -$6.47 falling short of the estimated -$6.12 by -5.72%, while revenue for the quarter reached $4.09m , beating expectations by +32.00%.
Earnings released on 12 Aug 2021
EPS came in at -$6.29 matching the estimated -$6.29, while revenue for the quarter reached $4.26m , missing expectations by -43.45%.
VYNE Stock Performance
Access detailed VYNE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
